A Phase 4 interventional study of Neuraceq (florbetaben 18F) and PET in Alzheimer's Disease (AD), sponsored by Lantheus Biosciences Ltd.. Completed at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Lantheus Biosciences Ltd. (part of Lantheus Holdings, Inc.) · Phase 4, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 438 studies in Alzheimer Disease with a site in France — 80 open to participants now, 97 under way, 19 of them phase 3. Alzheimer Disease · France.
Among the 438 studies in Alzheimer Disease with a site in France, this one is the 143rd largest by enrollment of the 342 interventional ones that give a count, is one of 20 that started in 2015, is one of 7 in phase 4, and was the 205th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →80 of the 438 studies in Alzheimer Disease with a site in France are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in France, United States, Australia and 2 more countries
Ages 50–90
Firalis SA · Sites in France
Ages 45+ · Healthy volunteers
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 60+ · Healthy volunteers
University Hospital, Toulouse · Sites in France
Ages 50–85
Central Hospital, Nancy, France · Sites in France
Ages 18–99
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
438 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 72 · Phase 3 88 · Phase 4 7
First in 2001; this study’s year is marked. 20 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 218 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 154 across the 342 interventional studies, 140 across the 93 observational. Of the 290 that completed or were terminated, 74 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
156 of 438 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lantheus Biosciences Ltd., one of the names counted as Lantheus Holdings, Inc.. Under that name alone:
Lantheus Biosciences Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Lantheus Holdings, Inc. has 7 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
32 of the studies in Alzheimer Disease with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06080659Rennes University HospitalNetwork-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity | 2026-11 |
| NCT06402838Hoffmann-La RocheA Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | 2026-11-19 |
Add all 32 to your calendar (.ics) → With an account.
Among the 438 studies in Alzheimer Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase 4 study will explore, in the context of the present French clinical practice, the impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for etiologic determination of the cognitive and functional impairment, but in whom:
It will be conducted in an outpatient setting at the tertiary memory clinics (CMRR) in France in patients with a preliminary diagnosis based on the completion of a prior, full diagnostic workup, not more than 12 months previously - which could include, but will not be limited to brain imaging if needed (magnetic resonance imaging (MRI) or computed tomography (CT)), neuropsychological evaluation including a Mini-Mental Status Examination (MMSE), CSF examination and other examinations according to "Haute Autorité de santé" (HAS, National Authority of Health, France) Recommendations - and in whom:
For all subjects the study will comprise 3 outpatient clinic visits to record information on previous work ups and to perform the FBB Positron Emission Tomography (PET) scan (Visit 1: screening/ baseline, Visit 2: PET scan, Visit 3: subject informed on the FBB PET scan result).
At Visit 1, the initial diagnosis based on previous work up will be collected and rated on a five-point Likert confidence scale by the Physician.
At Visit 2, the FBB PET scan will be performed. Adverse events will be reported during the exam and up to 7 days after the PET procedure.
At Visit 3, based on the amyloid PET scan results, change of diagnosis will be collected, in addition to physician confidence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject. The applied florbetaben radioactive dose will be ± 20%.
Drug: Neuraceq (florbetaben 18F) · Procedure: PET
Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
Also known as: FBB
A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
Also known as: Positron Emission Tomography
Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan Outcomes
The Physician's diagnosis was assessed before and after FBB PET scan. The initial Physician's diagnosis was collected before the PET scan, at Visit 1, based on key diagnostic results of current or previous workup. After the PET scan, the final Physician's diagnosis was collected at Visit 3, based on the amyloid PET scan results.
Time frame: Visit 1 (baseline evaluation) and Visit 3 (up to 6 months later)
Number of Subjects With Improved Level of Physician Confidence in Diagnosis at Visit 3
The Physician's diagnostic confidence was rated on a five-point Likert scale before and after FBB PET scan. Likert scales consisted of the categories: "very weak", "weak", "moderate", "high", and "very high".
Time frame: Visit 1 (baseline evaluation) and Visit 3 (up to 6 months later)
Number of Participants With a Change of Management Plan Comparing Pre- and Post-scan Outcomes
For all subjects, concomitant medications were reported and any change of the management plan (e.g. new medications initiated, medications withdrawn, additional diagnostic tests ordered, referred to another specialist) was noted.
Time frame: Visit 1 (baseline evaluation) and Visit 3 (up to 3 months later)
Number of Subjects With Positive FBB PET Scan
PET image interpretation was performed locally in each centre by readers who had undergone training for appropriate interpretation of scans. Scans were interpreted as either "positive" or "negative" according to the approved visual assessment method.
Time frame: Visit 3 (up to 6 months after baseline evaluation)
Number of Subjects With Negative FBB PET Scans
PET image interpretation was performed locally in each centre by readers who had undergone training for appropriate interpretation of scans. Scans were interpreted as either "positive" or "negative" according to the approved visual assessment method.
Time frame: Visit 3 (up to 6 months after baseline evaluation)
Number of Subjects With Contraindicated or Failed Lumbar Puncture
Number of subjects with contraindicated or failed LP (anticoagulant therapy, thrombocytopenia, lumbar puncture failed, spinal problems)
Time frame: Visit 1 (baseline evaluation)
Number of Subjects With Available CSF Analysis But Results Considered as Non-contributory by the Clinician
Non-contributory CSF results (ambiguous CSF result, CSF result inconsistent with clinical information, uninterpretable CSF result for technical reasons)
Time frame: Visit 1 (baseline evaluation)
Number of Subjects Who Refused Lumbar Puncture.
Time frame: Visit 1 (baseline evaluation)
This was a Phase IV, multi-center study which was conducted in an outpatient setting documenting routine clinical care in the Centres Mémoire Ressources et Recherches (CMRR). Subjects were recruited in 18 active centers in France.
| Milestone | Neuraceq (Florbetaben 18F) PET Scan |
|---|---|
| Started | 218 |
| Safety analysis set | 205 |
| Full analysis set | 205 |
| Per protocol set | 205 |
| Completed | 205 |
| Not completed | 13 |
The Physician's diagnosis was assessed before and after FBB PET scan. The initial Physician's diagnosis was collected before the PET scan, at Visit 1, based on key diagnostic results of current or previous workup. After the PET scan, the final Physician's diagnosis was collected at Visit 3, based on the amyloid PET scan results.
| Participants | Safety Analysis Set |
|---|---|
| Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan Outcomes | 137 |
The Physician's diagnostic confidence was rated on a five-point Likert scale before and after FBB PET scan. Likert scales consisted of the categories: "very weak", "weak", "moderate", "high", and "very high".
| Participants | Safety Analysis Set |
|---|---|
| Number of Subjects With Improved Level of Physician Confidence in Diagnosis at Visit 3 | 167 |
For all subjects, concomitant medications were reported and any change of the management plan (e.g. new medications initiated, medications withdrawn, additional diagnostic tests ordered, referred to another specialist) was noted.
| Participants | Safety Analysis Set |
|---|---|
| Number of Participants With a Change of Management Plan Comparing Pre- and Post-scan Outcomes | 164 |
PET image interpretation was performed locally in each centre by readers who had undergone training for appropriate interpretation of scans. Scans were interpreted as either "positive" or "negative" according to the approved visual assessment method.
| Participants | Safety Analysis Set |
|---|---|
| Number of Subjects With Positive FBB PET Scan | 132 |
PET image interpretation was performed locally in each centre by readers who had undergone training for appropriate interpretation of scans. Scans were interpreted as either "positive" or "negative" according to the approved visual assessment method.
| Participants | Safety Analysis Set |
|---|---|
| Number of Subjects With Negative FBB PET Scans | 73 |
Number of subjects with contraindicated or failed LP (anticoagulant therapy, thrombocytopenia, lumbar puncture failed, spinal problems)
| Participants | Safety Analysis Set |
|---|---|
| Number of Subjects With Contraindicated or Failed Lumbar Puncture | 45 |
Non-contributory CSF results (ambiguous CSF result, CSF result inconsistent with clinical information, uninterpretable CSF result for technical reasons)
| Participants | Safety Analysis Set |
|---|---|
| Number of Subjects With Available CSF Analysis But Results Considered as Non-contributory by the Clinician | 87 |
| Participants | Safety Analysis Set |
|---|---|
| Number of Subjects Who Refused Lumbar Puncture. | 75 |
Collected over Adverse events were captured for up to 7 days after the PET scan procedure.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Analysis Set | 0/205 (0%) | 1/205 (0.5%) | 21/205 (10.2%) |
| Event | Safety Analysis Set |
|---|---|
| Cerebellar infarctNervous system disorders | 1/205 |
| Event | Safety Analysis Set |
|---|---|
| Injection Site ParaesthesiaGeneral disorders | 5/205 |
| Injection Site PainGeneral disorders | 4/205 |
| Injection Site HaematomaGeneral disorders | 2/205 |
| GlaucomaEye disorders | 1/205 |
| NauseaGastrointestinal disorders | 1/205 |
| FatigueGeneral disorders | 1/205 |
| InflammationGeneral disorders | 1/205 |
| DehydrationMetabolism and nutrition disorders | 1/205 |
| Polymyalgia RheumaticaMusculoskeletal and connective tissue disorders | 1/205 |
| Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/205 |
All subjects who received any amount of florbetaben were included in the safety analysis set.
| Age, Continuous(years) | Neuraceq (Florbetaben 18F) PET Scan |
|---|---|
| Mean | 70.9 ± 9.7 |
| Sex: Female, Male(Participants) | Neuraceq (Florbetaben 18F) PET Scan |
|---|---|
| Female | 102 |
| Male | 103 |
Plan to share: No
The record gives a start of Oct 2015, a primary completion of Sep 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2018, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Florbetaben f-18